Maintenance olaparib significantly improved progression-free survival (PFS) in patients with platinum-sensitive relapsed ovarian cancer (PSROC) unselected for BRCA1 and/or BRCA2 mutation (BRCAm) status [3], and further in patients with a BRCAm who were in response to prior platinum-based chemotherapy [4], resulting in approval as maintenance therapy for patients with PSROC irrespective of BRCAm status [5–7]. The gene discussed is BRCA2; the disease is ovarian carcinoma.